Boosting bioavailability of topotecan: What do we gain?

Journal of Clinical Oncology

Volumn 20, Issue 13, 2002, Pages 2918-2919

  Hudes, Gary ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; TOPOTECAN;

AREA UNDER THE CURVE; BIOAVAILABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; EDITORIAL; HUMAN; PRIORITY JOURNAL;

EID: 0036645149     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.13.2918     Document Type: Editorial

References (10)

1. Patient preferences for oral versus intravenous palliative chemotherapy
2. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
3. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF 120918
4. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
5. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
6. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients
7. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors
8. Phase I study of topotecan with weekly 5-fluorouracil/leucovorin in patients with advanced malignancies: An update
9. Weekly topotecan combined with weekly paclitaxel in second- or third-line therapy of epithelial ovarian carcinoma
10. Co-administration of GF 120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients